FDA’s Novel Approvals Again Led By Oncology And Neurology, But Dermatology Also Shone In 2022
Executive Summary
Pink Sheet infographic breaks down the trends and surprises in 2022 approvals. Cancer therapies and non-malignant hematology exceeded the average use of expedited review programs but were weighted to orphan diseases, while dermatology saw first-in-class approvals for big markets.